Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/116868
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer |
Author: | Tie, J. Wang, Y. Tomasetti, C. Li, L. Springer, S. Kinde, I. Silliman, N. Tacey, M. Wong, H. Christie, M. Kosmider, S. Skinner, I. Wong, R. Steel, M. Tran, B. Desai, J. Jones, I. Haydon, A. Hayes, T. Price, T. et al. |
Citation: | Science Translational Medicine, 2016; 8(346):1-10 |
Publisher: | American Association for the Advancement of Science |
Issue Date: | 2016 |
ISSN: | 1946-6234 1946-6242 |
Statement of Responsibility: | Jeanne Tie, Yuxuan Wang, Cristian Tomasetti, Lu Li, Simeon Springer, Isaac Kinde … Tim J. Price … et al. |
Abstract: | Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may identify patients at the highest risk of recurrence and help inform adjuvant treatment decisions. We used massively parallel sequencing-based assays to evaluate the ability of ctDNA to detect minimal residual disease in 1046 plasma samples from a prospective cohort of 230 patients with resected stage II colon cancer. In patients not treated with adjuvant chemotherapy, ctDNA was detected postoperatively in 14 of 178 (7.9%) patients, 11 (79%) of whom had recurred at a median follow-up of 27 months; recurrence occurred in only 16 (9.8 %) of 164 patients with negative ctDNA [hazard ratio (HR), 18; 95% confidence interval (CI), 7.9 to 40; P < 0.001]. In patients treated with chemotherapy, the presence of ctDNA after completion of chemotherapy was also associated with an inferior recurrence-free survival (HR, 11; 95% CI, 1.8 to 68; P = 0.001). ctDNA detection after stage II colon cancer resection provides direct evidence of residual disease and identifies patients at very high risk of recurrence. |
Keywords: | Humans Colonic Neoplasms Neoplasm Recurrence, Local Neoplasm, Residual Neoplasm Staging Disease-Free Survival Proportional Hazards Models Prospective Studies Circulating Tumor DNA |
Rights: | Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. The title Science Translational Medicine is a registered trademark of AAAS. |
DOI: | 10.1126/scitranslmed.aaf6219 |
Published version: | http://dx.doi.org/10.1126/scitranslmed.aaf6219 |
Appears in Collections: | Aurora harvest 8 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.